SCHEMBL13431124

SCHEMBL13431124

CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H]1CC(O)CC(=O)O1

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 11/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30571418 1.00 HMGCR (0.74) HMGCR
SCHEMBL12897943 1.00 HMGCR (0.74) HMGCR
SCHEMBL18269413 1.00 HMGCR (0.74) HMGCR
SCHEMBL3221050 1.00 HMGCR (0.74) HMGCR
SCHEMBL245092 1.00 HMGCR (0.74) HMGCR
SCHEMBL13625375 1.00 HMGCR (0.74) HMGCR
SCHEMBL14669553 1.00 HMGCR (0.74) HMGCR
SCHEMBL245091 1.00 HMGCR (0.74) HMGCR
SCHEMBL30571404 1.00 HMGCR (0.74) HMGCR
SCHEMBL13764732 1.00 HMGCR (0.74) HMGCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150518-B2 Process for preparing amorphous rosuvastatin calcium of impurities LEK PHARMACEUTICALS, D.D. 2015-10-06 US disclosed
US-20100069635-A1 ROSUVASTATIN DEHYDROABIETYLAMINE SALT DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-18 US disclosed
US-20100069635-A1 ROSUVASTATIN DEHYDROABIETYLAMINE SALT DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-18 US disclosed
US-20090111839-A1 Process for Preparing Amorphous Rosuvastatin Calcium of Impurities LEK PHARMACEUTICALS D.D. (SI) 2009-04-30 US disclosed
US-20070255060-A1 Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof ASTRAZENECA UK LIMITED (GB) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069635-A1 ROSUVASTATIN DEHYDROABIETYLAMINE SALT HMGCR, DHCR7, PCSK9 HMGCR 1/4885
US-20090111839-A1 Process for Preparing Amorphous Rosuvastatin Calcium of Impurities HMGCR, PCSK9, CACNA2D1 HMGCR 1/4885
US-20070255060-A1 Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof HMGCR, DHCR7, FADS2 HMGCR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.